A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib.

Shuang Dai,Xiao-Qin Liu,Qiang Wu, Chun-Mei Du,Qing Liu, Yin-Yin Xue,Feng Luo,Yan Li

Lung cancer (Amsterdam, Netherlands)（2022）

引用 0|浏览3

暂无评分

摘要

This case introduces a novel and meaningful ALK fusion type in LUAD with sustained sensitivity to crizotinib, providing a reference to the treatment of similar cases with SETD3-ALK fusion in the future.

查看译文

关键词

Crizotinib,Lung adenocarcinoma,Next-generation sequencing (NGS),SETD3-ALK

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要